Patent application number | Description | Published |
20110175977 | METHOD, SYSTEM, AND COMPUTER-READABLE STORAGE MEDIUM FOR REMOTE CONTROL OF A VIDEO CONFERENCING DEVICE - A method, system, and computer-readable storage medium for remotely controlling a video conferencing device registered with a video conferencing management server. The method includes establishing a connection to the video conferencing management server via a local access network (LAN), receiving a list of video conferencing devices registered with the video conferencing management server, selecting a video conferencing device from the list of video conferencing devices registered with the video conferencing management server, downloading a remote control application from the video conferencing management server, receiving registration information for the selected video conferencing device from the video conferencing management server, the registration information including at least an internal LAN address of the selected video conferencing device, establishing, using the registration information, a connection directly with the selected video conferencing device, and controlling the selected video conferencing device using the remote control application. | 07-21-2011 |
20110310212 | SYSTEM AND METHOD FOR VERIFYING A VIDEO CALL NUMBER ENTRY IN A DIRECTORY - A system and method allowing users of video call endpoints to register their video call addresses in a local, regional and/or global directory, where the directory is configured to validate whether the video call address is a valid accessible address and that the user registering the video call number actually has physical access to the a video call device using the video call address. | 12-22-2011 |
Patent application number | Description | Published |
20090176234 | Efficient base determination in sequencing reactions - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods. | 07-09-2009 |
20090176652 | Methods and Oligonucleotide Designs for Insertion of Multiple Adaptors into Library Constructs - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 07-09-2009 |
20090203551 | Methods and Oligonucleotide Designs for Insertion of Multiple Adaptors Employing Selective Methylation - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 08-13-2009 |
20100105052 | Nucleic acid sequencing and process - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods. | 04-29-2010 |
20120100534 | EFFICIENT BASE DETERMINATION IN SEQUENCING REACTIONS - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods. | 04-26-2012 |
20120122699 | Methods and Oligonucleotide Designs for Insertion of Multiple Adaptors Employing Selective Methylation - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 05-17-2012 |
Patent application number | Description | Published |
20130317913 | CAMPAIGN REWARD SYSTEM IN COMMUNICATION WITH FINANCIAL INSTITUTION - A campaign offer system provides an offer using a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a use. The service provider is in communication with an advertiser, a retailer and a financial institution. A retailer gateway is in communication with a retailer checkout system that has a unique identifier for each retailer checkout location captured by the mobile device. The unique identifier is transmitted to the service provider which effects transactions between the user and the retailer checkout system via the retailer gateway. The service provider invoices the advertiser for the offer with redemption information. | 11-28-2013 |
20130325570 | CAMPAIGN REWARD SYSTEM WITH FINANCIAL RECONSOLIDATION - A campaign offer system provides an offer using a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a use. The service provider is in communication with an advertiser, a retailer and a financial institution. A retailer gateway is in communication with a retailer checkout system that has a unique identifier for each retailer checkout location captured by the mobile device. The unique identifier is transmitted to the service provider which effects transactions between the user and the retailer checkout system via the retailer gateway. The system prepares a report for the retailer that includes redemption data for the offers redeemed at the retailer with enough data to identify a specific redemption. | 12-05-2013 |
20130339135 | CAMPAIGN REWARD SYSTEM WITH CAMPAIGN MODIFICATION - A campaign offer system provides an offer with the use of a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a user. The service provider is in communication with an advertiser and a retailer. A retailer gateway communicates with a retailer checkout system via existing retailer checkout system peripheral device communication protocols without a need to modify the communications protocols or modify a retailer checkout system software code. An advertiser creates an offer campaign with details of the offer campaign stored in the database. The details include at least one of, offer distribution rules and offer redemption rules. | 12-19-2013 |
20130339143 | CAMPAIGN REWARD SYSTEM WITH TARGETING OF USERS FOR OFFERS - A campaign offer system provides an offer with the use of a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a user. The service provider is in communication with an advertiser and a retailer. A retailer gateway communicates with a retailer checkout system via existing retailer checkout system peripheral device communication protocols without a need to modify the communications protocols or modify a retailer checkout system software code. An advertiser creates an offer campaign with details including at least one of, offer distribution rules and offer redemption rules for targeting users for offers. | 12-19-2013 |
20140046759 | CAMPAIGN REWARD SYSTEM WITH SORTING OF OFFERS TO USERS - A campaign offer system provides an offer using a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a user. The service provider is in communication with an advertiser and a retailer. A retailer gateway communicates with a retailer checkout system via existing retailer checkout system peripheral device communication protocols without a need to modify the communications protocols or modify a retailer checkout system software code. The system in operation sorts offers for different users. | 02-13-2014 |
20140052521 | CAMPAIGN REWARD SYSTEM IN COMMUNICATION WITH FINANCIAL INSTITUTION - A campaign offer system provides an offer using a mobile device. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a use. The service provider is in communication with an advertiser, a retailer and a financial institution. A retailer gateway is in communication with a retailer checkout system that has a unique identifier for each retailer checkout location captured by the mobile device. The unique identifier is transmitted to the service provider which effects transactions between the user and the retailer checkout system via the retailer gateway. The service provider invoices the advertiser for the offer with redemption information. | 02-20-2014 |
20140058818 | Offer redemption of an offer at a retailer interface that identifies a retail transaction and line items used by offer validation - An offer redemption system is provided with least one computing device. An offer clearinghouse application is executable in the at least one computing device. The offer clearinghouse application includes, (i) one or more processes that receives details of an offer including at least one product to which n offer applies and at least one offer restriction for the offer, (ii) one or more processors that provides for distribution of the offer to users on behalf of an advertiser and (iii) one or more processors that provides for redemption of the offer with a retailer. A retailer interface receives, at a time of offer redemption, information to identify a retail transaction and line item used by an offer validation. | 02-27-2014 |
20140149196 | OFFER REDEMPTION OF AN OFFER AT A RETAILER - A system is provided for offer redemption of a retailer. A service provider includes one or more servers with engines and attached storage. The service provider is configured to be in communication with a mobile application running on a user mobile device of a user. The service provider is configured to be in communication with an advertiser and the retailer. The service provider is coupled to one or more processors with logic that enable an advertiser to create an offer campaign with details of the offer campaign stored in the storage. The details including at least one of, offer distribution rules and offer redemption rules. The one or more processors review transaction line items of the offer and making a determination to push or not push the offer redemption to a retailer check-out system. | 05-29-2014 |
Patent application number | Description | Published |
20090075203 | PHOTORESIST COMPOSITIONS COMPRISING DIAMONDOID DERIVATIVES - Novel positive-working photoresist compositions are disclosed. The monomers of the base resin of the resist contain diamondoid-containing pendant groups higher than adamantane in the polymantane series; for example, diamantane, triamantane, tetramantane, pentamantane, hexamantane, etc. The diamondoid-containing pendant group may have hydrophilic-enhancing substituents such as a hydroxyl group, and may contain a lactone group. Advantages of the present compositions include enhanced resolution, sensitivity, and adhesion to the substrate. | 03-19-2009 |
20100094012 | Heterodiamondoids - This invention is related to heteroatom containing diamondoids (i.e., “heterodiamondoids”) which are compounds having a diamondoid nucleus in which one or more of the diamondoid nucleus carbons has been substitutionally replaced with a noncarbon atom. These heteroatom substituents impart desirable properties to the diamondoid. In addition, the heterodiamondoids are functionalized affording compounds carrying one or more functional groups covalently pendant therefrom. This invention is further related to polymerizable functionalized heterodiamondoids. In a preferred aspect of this invention the diamondoid nuclei are triamantane and higher diamondoid nuclei. In another preferred aspect, the heteroatoms are selected to give rise to diamondoid materials which can serve as n- and p-type materials in electronic devices can serve as optically active materials. | 04-15-2010 |
20100112214 | Synthesis of Higher Diamondoids - In some embodiments, the present invention is directed to methods for synthesizing higher diamondoids, wherein said methods involve augmenting existing diamondoid molecules through the bonding of carbon atoms to such existing diamondoid species with intramolecular cross-linking so as to form larger diamondoids containing face-fused diamond-crystal (adamantane) cages with carbon frameworks superimposable on the cubic-diamond crystal lattice. | 05-06-2010 |
20100190985 | Heterodiamondoids - This invention is related to heteroatom containing diamondoids (i.e., “heterodiamondoids”) which are compounds having a diamondoid nucleus in which one or more of the diamondoid nucleus carbons has been substitutionally replaced with a noncarbon atom. These heteroatom substituents impart desirable properties to the diamondoid. In addition, the heterodiamondoids are functionalized affording compounds carrying one or more functional groups covalently pendant therefrom. This invention is further related to polymerizable functionalized heterodiamondoids. In a preferred aspect of this invention the diamondoid nuclei are triamantane and higher diamondoid nuclei. In another preferred aspect, the heteroatoms are selected to give rise to diamondoid materials which can serve as n- and p-type materials in electronic devices can serve as optically active materials. | 07-29-2010 |
20100221453 | BIAS ENHANCED NUCLEATION OF DIAMOND FILMS IN A CHEMICAL VAPOR DEPOSITION PROCESS - Diamonds are used to nucleate diamond and diamond-like carbon films in a chemical vapor deposition process using bias enhancement. A negative bias is applied to the substrate, such that a cationic form of the diamond is accelerated toward the substrate during the nucleation phase of the deposition. In this manner, the diamondoid may be embedded or partially embedded in the substrate and/or growing film, increasing the adhesion of the film to the substrate. According to the present embodiments, it is not necessary to mechanically pre-seed the substrate for nucleation purposes. | 09-02-2010 |
20110112258 | Polymerizable Higher Diamondoid Derivatives - Higher diamondoid derivatives capable of taking part in polymerization reactions are disclosed as well as intermediates to these derivatives, polymers formed from these derivatives and methods for preparing the polymers. | 05-12-2011 |
Patent application number | Description | Published |
20090054438 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA - There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof. | 02-26-2009 |
20100093734 | CYTOKINE INHIBITORS - The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis. | 04-15-2010 |
20100093735 | CYTOKINE INHIBITORS - The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis. | 04-15-2010 |
20100273797 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF - The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as arthritis. | 10-28-2010 |
20100305129 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA - There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof. | 12-02-2010 |
20110166216 | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma - There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof. | 07-07-2011 |
20110257233 | BENZOISOTHIAZOLONES AS INHIBITORS OF PHOSPHOMANNOSE ISOMERASE - The disclosure provides new compounds and compositions thereof, and methods for treating or ameliorating a disorder relating to CDG-Ia. In particular, the disclosure provides benzoisothiazolone inhibitors of PMI, which have been synthesized and their ability to drive glycosylation has been demonstrated. The disclosure provides two synthetic routes for these compounds, including a new copper-catalyzed N-arylation reaction amenable to parallel derivitization. The disclosed compounds represent potent inhibitors of PMI, and their dose-dependent efficacy in cell-based models of glycosylation have been demonstrated. In addition, the disclosed compounds are selective over PMM and therefore, are useful in treating or ameliorating a disorder relating to CDG-Ia. | 10-20-2011 |
20150218148 | Benzothiazole Or Benzoxazole Compounds As Sumo Activators - Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases. | 08-06-2015 |
Patent application number | Description | Published |
20080199427 | Novel pyridazine compound and use thereof - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 08-21-2008 |
20090036408 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 02-05-2009 |
20090143314 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 06-04-2009 |
20100063059 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided. | 03-11-2010 |
20140037724 | UNITARY PHARMACEUTICAL DOSAGE FORM - In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation. | 02-06-2014 |
20140037732 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 02-06-2014 |
20140213556 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 07-31-2014 |
20140370102 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 12-18-2014 |
20150111855 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 04-23-2015 |
20150111856 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 04-23-2015 |
20150174147 | UNITARY PHARMACEUTICAL DOSAGE FORM - In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation. | 06-25-2015 |
Patent application number | Description | Published |
20090012356 | ENDOSCOPIC DELIVERY DEVICES AND METHODS - Disclosed herein are various devices and methods that can be utilized independently or in conjunction with each other for endoscopic delivery of a wide ranges of medical devices, such as, for example, an endoscopic gastrointestinal bypass sleeve with an attachment cuff. Components of the system can include a space-creating device; an expandable fastener system with flower petal-shaped retention elements; and an endoscopic curved needle driver system. | 01-08-2009 |
20090012541 | EXPANDABLE FASTENER SYSTEM WITH FLOWER PETAL-SHAPED RETENTION ELEMENTS - Disclosed herein are various devices and methods that can be utilized independently or in conjunction with each other for endoscopic delivery of a wide ranges of medical devices, such as, for example, an endoscopic gastrointestinal bypass sleeve with an attachment cuff. Three primary components of the system include a space-creating device; an expandable fastener system with flower petal-shaped retention elements; and an endoscopic curved needle driver system. | 01-08-2009 |
20140207159 | DEVICES AND METHODS FOR DELIVERING AN ANCHORED DEVICE - One or more tissue anchors may be delivered first without being coupled to an anchored device. An anchored device may be delivered second, and then coupled to the tissue anchors. This may enhance placement accuracy of tissue anchors, as well as facilitate delivery of tissue anchors. The tissue anchors include anchor couplings configured to be coupled to one or more device couplings of the anchored device. | 07-24-2014 |